# US 2023/0015875 A1 · Ion Channel Antagonists/Blockers and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0015875 A1
- Document ID: US20230015875A1
- Status: Published application
- Kind: A1
- Application number: 17/755,398
- Filed: 2019-12-14
- Published: 2023-01-19
- Earliest claimed: 2019-12-14
- Assignees: Shanghai East Hospital
- Applicants: Shanghai East Hospital
- Inventors: Yihan Chen; Dandan Liang; Yi Liu; Subas Man Sakya; Jinhua Yang; Li Li; Duanyang Xie; Dan Shi; Ke Xiong
- Web page: https://patentgrep.com/patent/US20230015875A1

## CPC

- C07D 217/24: Oxygen atoms
- A61P 9/06: Antiarrhythmics
- C07C 39/14: with at least one hydroxy group on a condensed ring system containing two rings
- C07C 39/15: with all hydroxy groups on non-condensed rings {, e.g. phenylphenol}
- C07C 39/17: containing other rings in addition to the six-membered aromatic rings {, e.g. cyclohexylphenol}
- C07C 39/23: polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
- C07C 43/202: {the aromatic ring being a naphthalene}
- C07C 43/2055: {containing more than one ether bond}
- C07C 43/23: containing hydroxy or O-metal groups
- C07C 49/83: polycyclic
- C07C 53/06: Salts thereof
- C07C 63/38: containing two carboxyl groups both bound to carbon atoms of the condensed ring system
- C07C 65/11: with carboxyl groups on a condensed ring system containing two rings
- C07C 211/58: Naphthylamines; N-substituted derivatives thereof
- C07C 215/86: being formed by two rings
- C07C 233/65: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C 235/66: with carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and singly-bound oxygen atoms, bound to the same carbon skeleton
- C07C 311/08: having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C 311/24: of an acyclic saturated carbon skeleton
- C07C 311/29: having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C 317/22: with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07D 209/34: in position 2
- C07D 211/22: by oxygen atoms
- C07D 213/30: Oxygen atoms
- C07D 217/02: with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D 231/20: One oxygen atom attached in position 3 or 5
- C07D 235/26: Oxygen atoms
- C07D 241/42: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D 295/084: with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- G01N 33/502: {for testing non-proliferative effects}
- C07C 2601/10: the ring being unsaturated
- C07C 2601/16: the ring being unsaturated
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided are ion channel antagonists/blockers and uses thereof. Specifically, it provides the compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs, preparation method therefor and application thereof. Definition of each group in the formula can be found in the specification for details. Provided is also pharmaceutical composition useful for treatment of heart disease and other ion channel related diseases.

## Claims

### Claim 1

A compound of formula (I), or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a prodrug thereof:
wherein
each of ring Ar1 and ring Ar2 is independently selected from the group consisting of substituted or unsubstituted phenyl ring, substituted or unsubstituted naphthyl, substituted or unsubstituted biphenyl; with the proviso that ring Ar1 and ring Ar2 are not phenyl at the same time;
R1 is selected from the group: —O—, —S—, —N(Ra)—, —C(Rb)2—, —C(O)—, —C(S)—, —S(O)2—, —S(O)—;
R3 is selected from the group: —O—, —S—, —N(Ra)—, —C(Rb)2—, —C(O)—, —S(O)2—, —S(O)—, —C(O)NRf—, —NRfC(O)—;
L1 is selected from null, substituted or unsubstituted C3-C8 cycloalkyl or a substituted or unsubstituted C1-C6 alkylene group, substituted or unsubstituted C6-C14 aryl, unsubstituted 4 to 10 membered heterocyclic group, or substituted or unsubstituted 5- to 10-membered heteroaryl; wherein when L1 is C1-C6 alkylene, the carbon atom on the middle chain of L1 is optionally substituted with 0, 1 or 2 divalent groups selected from the group: —O—, —S—, —N(Ra)—, —C(O)—;
R7 is selected from the group consisting of: H, —OH, halogen, Rf—, Rf—O—, Rf—S—, Rf—C(O)O—, Rf—S(O) 2-, Rf—S(O)—, Rf—C(O)—, NHRf, NH(SO2)Rf, and —R1-L1-Rd; wherein Rf is selected from the group consisting of: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl; R1 and L1 is as defined above;
Re is selected from the group: —N(R2)2, —N+(R2)3,
q=0, 1 or 2;
each R8 is independently selected from the group consisting of: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 5- to 7-membered heteroaryl; substituted or unsubstituted 4 To 7-membered heterocycloalkyl;
each R2 is independently selected from the group consisting of: H, substituted or unsubstituted C1-C6 alkyl, —C(O)-substituted or unsubstituted C1-C6 alkyl; or two R2 and the nitrogen atom to which they are attached form a substituted or unsubstituted 4 to 10 membered heterocyclic group or 5 to 10-membered heteroaryl, and the heterocyclyl or heteroaryl contains 1-2 N atoms and 0, 1, 2 O or S heteroatoms;
Ra is selected from the group consisting of: H, substituted or unsubstituted C1-C4 alkyl;
Rb are each independently selected from the group consisting of H, —OH, cyano(-CN), substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C1-C6 alkoxy, and substituted or unsubstituted —S—C1-C4 alkyl;
Rc and Rd are independently selected from the group consisting of halogen —OH, nitro, cyano, sulfonyl, R″, —N(R″)2—, R″—O—, R″—S—, R″—S(O)2—, R″—S(O)—, R″—C(O), R″—C(O)O—, R″—OC(O)—;
n1 and n2 are independently 0, 1, 2, 3, 4 or 5;
unless otherwise specified, the term “substituted” refers to one or more hydrogens in the group is replaced with an R′ group;
each R′ is independently selected from the group consisting of D, halogen —OH, nitro, cyano, sulfonyl, R″, —N(R″), R″—O—, R″—S—, R″—S(O)2—, R″—S(O)—, R″—C(O), R″—C(O)O—, R″—OC(O)—, oxo (O═); or when two R′ attached to the same carbon atom, the two R′ and the carbon atom to which they are attached form substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 4 to 7 membered heterocyclic group or 5 to 7-membered heteroaryl
where R″ is each independently selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C10 aryl, 4- to 7-membered heterocycloalkyl, 5- to 7-membered heteroaryl, —C1-C4 alkylene-C3-C6 cycloalkyl, —C1-C4 alkylene-C6-C10 aryl, —C1-C4 alkylene-(4 to 7-membered heterocycloalkyl), —C1-C4 alkylene-(5 to 7-membered heteroaryl);
and in R″, the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocycloalkyl and heteroaryl, as a whole group or a partial group, can be optionally substituted by a substituent selected from the group consisting of: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, —OH, nitro, cyano, sulfonyl, and amino.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a prodrug thereof, wherein the compound has a structure of formula Ia:
wherein
R1, R3, R7, Rc, Rd, Re, L1, n1 and n2 are as defined in claim 1;
Rings A1 and A2 are each independently selected from the group consisting of: none, and substituted or unsubstituted benzene rings, with the proviso that rings A1 and A2 are not none at the same time;
wherein, the term “substituted” means that one or more hydrogens in the group are replaced by an R′ group; and R′ is as defined in claim 1.

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a prodrug thereof, wherein the compound has a structure of formula II:
wherein,
R1, R3, R7, Rc, Rd, R2, L1, n1, n2, ring A1 and ring A2 are as defined in claim 1.

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a prodrug thereof, wherein the compound of formula II is represented by formula IIa or IIb:
wherein, R1, R2, R3, R7, Rc, Rd, L1, n1, n2, ring A1 and ring A2 are as defined in claim 1.

### Claim 5 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a prodrug thereof, wherein the compound of formula II is represented by formula IIa or IIb:
wherein, R1, R2, R3, R7, Rc, Rd, L1, and ring A2 are as define in claim 1;
each of R′ are independently defined as in claim 1;
n1 and n2 are independently 0, 1 or 2; and
m=0, 1, 2, or 3.

### Claim 6 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a prodrug thereof, wherein the compound has a structure of formula IIg, IIh or IIi
wherein, R1, R2, R3, R7, Rc, Rd, L1, and R′ are as define in claim 1;
n1 and n2 are independently 0, 1 or 2; and
each of m is independently 0, 1, 2 or 3.

### Claim 7 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a prodrug thereof, wherein the compound has a structure of formula IIIa, IIIb or IIIc:
wherein,
R1 is O, NH, CH2, S, S(O) and S(O)2,
R2 is substituted or unsubstituted C1-C3 alkyl;
R3 is —NH—, —N(Ra)—, —CH2—, —C(O)—, —CHOH—, —S—, —SO—, or —SO2—;
R7 is selected from the group consisting of: H, F, Cl, Br, —OH, NHRf, NH(SO2)Rf, Rf—, Rf—O—, Rf—C(O)O—, Rf—S(O)2—, Rf—S(O)—, Rf—C(O)—, and —R1-L1-Rd; wherein Rf is selected from the group consisting of: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl; R1 and L1 is as defined in claim 1;
R4, R5, and R6 is independently selected from the group consisting of H, Cl, F, ORf, N(Rf)2, C(O)ORf, C(O)N(Rf)2—Rf, where Rf is as described in claim 1.

### Claim 8 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a prodrug thereof, wherein the compound has a structure of formula IIIa-1, IIIb-1 or IIIc-1:
wherein,
R1, R2, R3, R4, R5, R6, and R7 are as defined in claim 1.

### Claim 9 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a prodrug thereof, wherein the compound is any selected from Table A, Table 1, or Table 2.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a prodrug thereof; and a pharmaceutically acceptable carrier.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

A method for promoting growth of cardiomyocytes in vitro, which comprises a step of:
culturing cardiomyocyte in the presence of the compound of claim 1, or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a prodrug.

### Claim 13 (depends on 1)

A method for inhibiting ion channel in vitro, which comprises a step of:
contacting cardiomyocyte with the compound of claim 1, or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a prodrug, thereby inhibiting ion channel.

### Claim 14 (depends on 1)

A method for treating or preventing an ion channel related disease, which comprises a step of: administering the compound according to claim 1 or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a prodrug to a subject in need thereof.
